Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sirolimus Granules vs Tablets in Japanese Healthy Adults
NCT03765944Phase 1Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Dec 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sirolimus in vascular tumor, vascular malformations (VM), lymphangioleiomyomatosis (LAM) and 1 more (2 arms), sponsored by Nobelpharma Co., Ltd. Primary endpoint: Blood sirolimus concentration at 72 hours. Started Dec 2018; status: completed.
02
Drugs
sirolimus
03
Conditions
vascular tumorvascular malformations (VM)lymphangioleiomyomatosis (LAM)tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on NCT03765944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765944.